Back to top
more

Exact Sciences (EXAS)

(Real Time Quote from BATS)

$46.65 USD

46.65
1,347,766

-1.11 (-2.32%)

Updated Aug 4, 2025 01:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Surging Earnings Estimates Signal Good News for Exact Sciences Corporation (EXAS)

by Zacks Equity Research

Exact Sciences Corporation (EXAS) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.

    Zacks Equity Research

    Exact Sciences Corporation (EXAS) Jumps: Stock Rises 6.2%

    by Zacks Equity Research

    Exact Sciences Corporation (EXAS) was a big mover last session, as the company saw its shares rise nearly 6% on the day after the company delivered yet another quarter of greater than 100% top-line growth.

      Zacks Equity Research

      Is a Beat in the Cards for ImmunoGen (IMGN) in Q2 Earnings?

      by Zacks Equity Research

      ImmunoGen has made significant progress with its ovarian cancer pipeline candidate. Let's see if the company can come up with a beat this earnings season.

        Zacks Equity Research

        Why Exact Sciences (EXAS) Might Surprise This Earnings Season

        by Zacks Equity Research

        Exact Sciences (EXAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

          Tirthankar Chakraborty headshot

          New Strong Buy Stocks for July 19th

          by Tirthankar Chakraborty

          Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday

            Tirthankar Chakraborty headshot

            New Strong Buy Stocks for July 17th

            by Tirthankar Chakraborty

            Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday

              Zacks Equity Research

              Why Exact Sciences (EXAS) Could Beat Earnings Estimates Again

              by Zacks Equity Research

              Exact Sciences (EXAS) boasts a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.

                Zacks Equity Research

                Exact Sciences (EXAS) Shows Strength: Stock Gains 11.7%

                by Zacks Equity Research

                Exact Sciences Corp. (EXAS) shares jumped almost 12% in the last trading session.

                  Zacks Equity Research

                  Pfizer's Leukemia Candidate Gets Priority Review in U.S.

                  by Zacks Equity Research

                  Pfizer Inc. (PFE) announced that its Biologics License Application (BLA) for leukemia candidate inotuzumab ozogamicin has been accepted for priority review by the FDA.

                    Zacks Equity Research

                    Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?

                    by Zacks Equity Research

                    Exelixis, Inc. (EXEL) is scheduled to report fourth-quarter 2016 results on Feb 27, after the market close.

                      Zacks Equity Research

                      Ionis (IONS) Q4 Earnings: What's in the Cards for the Stock?

                      by Zacks Equity Research

                      Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report fourth-quarter 2016 results on Feb 28.

                        Zacks Equity Research

                        Drug Stocks Q4 Earnings Lineup for Feb 21: IRWD, MNTA, EXAS

                        by Zacks Equity Research

                        Here we have three pharma companies that are set to report fourth-quarter results on Feb 21. Let's see how things are shaping up for this quarter.

                          Zacks Equity Research

                          Merrimack (MACK): What Awaits the Stock in Q4 Earnings?

                          by Zacks Equity Research

                          Merrimack Pharmaceuticals, Inc. (MACK) is scheduled to report fourth-quarter 2016 results in the next week. Last quarter, Merrimack delivered a positive earnings surprise of 23.33%.

                            Zacks Equity Research

                            Geron (GERN) Q4 Earnings: What's in Store for the Stock?

                            by Zacks Equity Research

                            Geron Corporation (GERN) is expected to report fourth-quarter 2016 results next week. In the last reported quarter, the company recorded a positive earnings surprise of 66.67%.

                              Zacks Equity Research

                              Can Fitbit (FIT) Stock Surprise Investors Post Q4 Earnings?

                              by Zacks Equity Research

                              Fitbit Inc. (FIT) is set to report fourth-quarter 2016 results on Feb 22. Last quarter, the company posted a positive earnings surprise of 18.18%.

                                Zacks Equity Research

                                BioMarin (BMRN) Q4 Earnings: Will it Post a Beat Again?

                                by Zacks Equity Research

                                We expect BioMarin Pharmaceutical Inc. (BMRN) to beat expectations when it reports fourth-quarter and full-year 2016 results on Feb 23

                                  Zacks Equity Research

                                  Alexion (ALXN) Q4 Earnings In-Line, Sales Rise Y/Y

                                  by Zacks Equity Research

                                  Alexion Pharmaceuticals, Inc.'s (ALXN) fourth-quarter 2016 earnings (including stock-based compensation expense) of $1.10 cents per share compared with the year ago earnings of 78 cents.

                                    Zacks Equity Research

                                    Alkermes (ALKS) Q4 Loss Narrower than Expectations, Sales Beat

                                    by Zacks Equity Research

                                    Alkermes plc (ALKS) reported loss of 4 cents per share (including the impact of share-based compensation expense) in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 19 cents.

                                      Zacks Equity Research

                                      Ligand (LGND) Q4 Earnings: Will the Stock Pull a Surprise?

                                      by Zacks Equity Research

                                      Ligand Pharmaceuticals Incorporated (LGND) is scheduled to report fourth-quarter 2016 results on Feb 23, after the market closes.

                                        Zacks Equity Research

                                        What's in Store for ImmunoGen (IMGN) this Earnings Season?

                                        by Zacks Equity Research

                                        ImmunoGen, Inc. (IMGN) is scheduled to report results for the three months ended Dec 31, 2016 on Feb 17, before the opening bell. Overall, the company has posted an average negative surprise of 19.34%.

                                          Zacks Equity Research

                                          The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals

                                          by Zacks Equity Research

                                          The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals

                                            Swarup Gupta headshot

                                            5 Great Biotech Stocks to Buy Now

                                            by Swarup Gupta

                                            Biotechs have stabilized and still offer the potential to deliver substantial returns.

                                              Zacks Equity Research

                                              Cara Therapeutics (CARA) Worth Watching: Stock Jumps 8%

                                              by Zacks Equity Research

                                              Cara Therapeutics, Inc. (CARA) was a big mover last session, as the company saw its shares climb over 8% on the day.

                                                Zacks Equity Research

                                                Pfizer (PFE) C. Difficile Vaccine Positive in Phase II Study

                                                by Zacks Equity Research

                                                Pfizer Inc. (PFE) announced positive top-line results from a phase II study on its investigational vaccine candidate, PF-06425090, for the prevention of clostridium difficile infection.

                                                  Zacks Equity Research

                                                  Vertex Pharma's (VRTX) Q4 Earnings & Sales Beat; Stock Up

                                                  by Zacks Equity Research

                                                  Vertex Pharmaceuticals Inc. (VRTX) reported fourth-quarter 2016 earnings of 11 cents per share (including the impact of stock-based compensation expenses). The Zacks Consensus Estimate was of a loss of 1 cent per share.